AbbVie's head of global head of immunology discovery research says the ability to profile patients at the molecular level has the potential to dramatically change treatment for people living with chronic conditions.
New testing means patients no longer 'defined by their symptoms'
February 26, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
Surely this therapy is an example of our system at its absolute worst?
June 28, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Guild says pharmacy a solution as AMA flags ambulance ramping crisis
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News


